SE0100684D0 - New subject-matter - Google Patents

New subject-matter

Info

Publication number
SE0100684D0
SE0100684D0 SE0100684A SE0100684A SE0100684D0 SE 0100684 D0 SE0100684 D0 SE 0100684D0 SE 0100684 A SE0100684 A SE 0100684A SE 0100684 A SE0100684 A SE 0100684A SE 0100684 D0 SE0100684 D0 SE 0100684D0
Authority
SE
Sweden
Prior art keywords
subject matter
new subject
cervicitis
situ
disclosed
Prior art date
Application number
SE0100684A
Other languages
English (en)
Swedish (sv)
Inventor
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Original Assignee
Kerstin Uvnaes Moberg
Thomas Lundeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kerstin Uvnaes Moberg, Thomas Lundeberg filed Critical Kerstin Uvnaes Moberg
Priority to SE0100684A priority Critical patent/SE0100684D0/xx
Publication of SE0100684D0 publication Critical patent/SE0100684D0/xx
Priority to US10/469,255 priority patent/US7405200B2/en
Priority to DE60239670T priority patent/DE60239670D1/de
Priority to PCT/SE2002/000362 priority patent/WO2002067974A1/en
Priority to EP02701842A priority patent/EP1370277B1/de
Priority to JP2002567340A priority patent/JP2004527496A/ja
Priority to AT02701842T priority patent/ATE504309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0100684A 2001-02-28 2001-02-28 New subject-matter SE0100684D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0100684A SE0100684D0 (sv) 2001-02-28 2001-02-28 New subject-matter
US10/469,255 US7405200B2 (en) 2001-02-28 2002-02-28 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
DE60239670T DE60239670D1 (de) 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
PCT/SE2002/000362 WO2002067974A1 (en) 2001-02-28 2002-02-28 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
EP02701842A EP1370277B1 (de) 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
JP2002567340A JP2004527496A (ja) 2001-02-28 2002-02-28 新規物質
AT02701842T ATE504309T1 (de) 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100684A SE0100684D0 (sv) 2001-02-28 2001-02-28 New subject-matter

Publications (1)

Publication Number Publication Date
SE0100684D0 true SE0100684D0 (sv) 2001-02-28

Family

ID=20283165

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100684A SE0100684D0 (sv) 2001-02-28 2001-02-28 New subject-matter

Country Status (7)

Country Link
US (1) US7405200B2 (de)
EP (1) EP1370277B1 (de)
JP (1) JP2004527496A (de)
AT (1) ATE504309T1 (de)
DE (1) DE60239670D1 (de)
SE (1) SE0100684D0 (de)
WO (1) WO2002067974A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
AR038085A1 (es) * 2002-12-27 2004-12-29 Univ Nac Quilmes Analogos de 1-desamino-8-d-arginina vasopresina
WO2009039983A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100061680A (ko) * 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｇｌｙ－ｐｒｏ－ｇｌｕ－ｏｈ（ｇｐｅ）의 용도
AU2008303955A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of Pseudomonas aeruginosa infection
WO2009040020A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
WO2019060962A1 (en) * 2017-09-28 2019-04-04 The University Of Sydney SELECTIVE AGONISTS OF THE OCYTOCIN RECEPTOR, INSPIRED BY METABOLITES
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
CS255616B1 (cs) * 1986-07-18 1988-03-15 Petr Simek Způsob výroby (2-0-metyltyrosin)deamino-1-karbaoxytocinu
DE4229878A1 (de) * 1992-09-04 1994-03-10 Knauf Siegfried Neues Medikament "Oxytocin" zur Bekämpfung der Zuckerkrankheit Typ 1
DE4236293A1 (en) * 1992-10-23 1993-03-04 Siegfried Knauf Use of oxytocin, vasopressin and endorphins - for treatment and prevention of e.g. immunological, neurological and organ diseases and conditions caused by pituitary disorder
DE4244639A1 (de) * 1992-10-23 1994-07-07 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
GB9326354D0 (en) 1993-12-23 1994-02-23 British Aerospace Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9803272D0 (sv) * 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
SE0102910D0 (sv) * 2001-08-31 2001-08-31 Moberg Kerstin Uvnaes New use

Also Published As

Publication number Publication date
ATE504309T1 (de) 2011-04-15
EP1370277A1 (de) 2003-12-17
DE60239670D1 (de) 2011-05-19
EP1370277B1 (de) 2011-04-06
US7405200B2 (en) 2008-07-29
US20040176284A1 (en) 2004-09-09
WO2002067974A1 (en) 2002-09-06
JP2004527496A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
GB0225474D0 (en) Therapeutic agents
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
MY138883A (en) Use of asiatic acid for treatment of cencer
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
TR200101120T2 (tr) Serin proteaz inhibitörü
ATE495187T1 (de) Dalda-analoge und ihre verwendung
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
BR9912327A (pt) Inibidores da uroquinase
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE9802208D0 (sv) Novel compounds
GB0130677D0 (en) Medicaments and novel compounds
ATE238981T1 (de) Antitumorwirkstoffe
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
IL124015A0 (en) Pharmaceutical compositions comprising a protein
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
GB9907571D0 (en) Compounds
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis